Alkermes plc (ALKS:NASDAQ) closed at $47.03 on November 13, 2026, up 0.11% on the day. The stock trades 15.5% below its 52-week high of $55.67 and 74.2% above its 52-week low of $27.00. Over the past year, it gained 61.9%. Alkermes plc is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, ALKS closed higher on 123 days (49%). Its best day was March 31, 2026 (+17.28%) and its worst was September 18, 2026 (-7.11%). The stock moved 10% or more in a single session 1 time. It opened at least 5% above the previous day's high 1 time.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which...
Find more stocks like ALKS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.